0001551152 false Common Stock, par value $0.01 per share ABBV 0001551152 2020-05-07 2020-05-08 0001551152 us-gaap:CommonStockMember exch:XCHI 2020-05-07 2020-05-08 0001551152 us-gaap:CommonStockMember exch:XNYS 2020-05-07 2020-05-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

Common Stock, par value $0.01 per share ABBV

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 8, 2020

 

ABBVIE INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-35565   32-0375147
(State or other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

 

 

1 North Waukegan Road

North Chicago, Illinois 60064-6400

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (847) 932-7900

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on
which registered

Common Stock, par value $0.01 per share

ABBV

 

New York Stock Exchange

Chicago Stock Exchange

 

 

 

 

 

Item 5.07.  Submission of Matters to a Vote of Security Holders.

 

AbbVie Inc. (“AbbVie”) held its Annual Meeting of Stockholders on May 8, 2020. The following is a summary of the matters voted on at that meeting.

 

(1)The stockholders elected AbbVie’s Class II Directors with terms expiring in 2023, as follows:

 

Name   For   Against   Broker Non-Votes
Robert J. Alpern   1,020,123,196   22,223,090   251,100,201
Edward M. Liddy   1,023,302,016   19,044,270   251,100,201
Melody B. Meyer   1,035,823,592   6,522,694   251,100,201
Frederick H. Waddell   1,034,247,294   8,098,992   251,100,201

 

(2)The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2020, as follows:

 

For   Against   Abstain    
1,283,070,625   8,155,121   2,220,741    

 

(3)The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers listed in the proxy statement for the 2020 annual meeting, as follows:

 

For   Against   Abstain   Broker Non-Votes
979,032,010   58,236,949   5,077,327   251,100,201

 

(4)The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows:

 

For   Against   Abstain   Broker Non-Votes
1,027,560,236   11,052,301   3,733,749   251,100,201

 

(5)The stockholders did not approve a stockholder proposal to issue a lobbying report, as follows:

 

For   Against   Abstain   Broker Non-Votes
305,759,857   722,755,468   13,830,961   251,100,201

 

(6)The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair, as follows:

 

For   Against   Abstain   Broker Non-Votes
287,051,093   749,233,839   6,061,354   251,100,201

 

(7)The stockholders did not approve a stockholder proposal to issue an annual Compensation Committee report on drug pricing, as follows:

 

For   Against   Abstain   Broker Non-Votes
249,382,082   773,211,511   19,752,693   251,100,201

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABBVIE INC.
   
   
Date:   May 12, 2020 By: /s/ Laura J. Schumacher
    Laura J. Schumacher
    Vice Chairman, External Affairs, Chief Legal Officer, and Corporate Secretary